144 related articles for article (PubMed ID: 16594237)
1. Conversion disorder with convulsion and motor deficit mimicking the adverse effects of high-dose Ara-C treatment in a posttransplant acute myeloid leukemia patient: a case report and review of the literature.
Onishi H; Kamijo A; Onose M; Yamada T; Mizuno Y; Ito M; Saito H; Maruta I
Palliat Support Care; 2004 Mar; 2(1):79-82. PubMed ID: 16594237
[TBL] [Abstract][Full Text] [Related]
2. [Results of therapy with high-dose cytosine arabinoside].
Pralle H; Breithaupt H
Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Lemez P; Urbánek V
Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
[TBL] [Abstract][Full Text] [Related]
4. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
Kumagawa M; Suzuki K; Nagano M; Takamatsu Y; Suzumiya J; Tamura K
Rinsho Ketsueki; 2003 Jun; 44(6):404-6. PubMed ID: 12884821
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH
N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301
[TBL] [Abstract][Full Text] [Related]
6. Contribution of single-photon emission computed tomography in the diagnosis and follow-up of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia.
Véra P; Rohrlich P; Stiévenart JL; Elmaleh M; Duval M; Bonnin F; Bok B; Vilmer E
J Clin Oncol; 1999 Sep; 17(9):2804-10. PubMed ID: 10561356
[TBL] [Abstract][Full Text] [Related]
7. Cytosine arabinoside-induced vasculitis.
Ahmed I; Chen KR; Nakayama H; Gibson LE
Mayo Clin Proc; 1998 Mar; 73(3):239-42. PubMed ID: 9511781
[TBL] [Abstract][Full Text] [Related]
8. Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia.
Altundag O; Altundag K; Celik I; Turker A; Kars A
Am J Hematol; 2004 Apr; 75(4):263-4. PubMed ID: 15054828
[No Abstract] [Full Text] [Related]
9. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
10. Cytarabine induced cerebellar neuronal damage in juvenile rat: correlating neurobehavioral performance with cellular and genetic alterations.
Patel RS; Rachamalla M; Chary NR; Shera FY; Tikoo K; Jena G
Toxicology; 2012 Mar; 293(1-3):41-52. PubMed ID: 22212197
[TBL] [Abstract][Full Text] [Related]
11. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
12. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
[TBL] [Abstract][Full Text] [Related]
13. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
[TBL] [Abstract][Full Text] [Related]
14. Brief psychotic disorder associated with bereavement in a patient with terminal-stage uterine cervical cancer: a case report and review of the literature.
Onishi H; Onose M; Yamada T; Mizuno Y; Ito M; Sugiura K; Kato H; Nakayama H
Support Care Cancer; 2003 Jul; 11(7):491-3. PubMed ID: 12690544
[TBL] [Abstract][Full Text] [Related]
15. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Damon LE; Rugo HS; Ries CA; Linker CA
Leukemia; 1994 Apr; 8(4):535-41. PubMed ID: 8152248
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytarabine and recombinant human granulocyte colony-stimulating factor for the treatment of resistant acute myelogenous leukemia.
Schiller G; Emmanoulides C; Iastrebner MC; Lee M; Naeim F
Leuk Lymphoma; 1996 Feb; 20(5-6):427-34. PubMed ID: 8833398
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
18. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman.
Friedman JH; Shetty N
Mov Disord; 2001 May; 16(3):575-7. PubMed ID: 11391764
[TBL] [Abstract][Full Text] [Related]
19. Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome.
Tanaka M; Kanamori H; Yamaji S; Mishima A; Fujita H; Fujisawa S; Murata T; Koharazawa H; Matsuzaki M; Mohri H
Anticancer Drugs; 1999 Mar; 10(3):289-91. PubMed ID: 10327034
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
